Breast cancer is one of the leading causes of death for women. Several subtypes exist. We are investigating a particularly dangerous and aggressive strain that overexpresses the growth factor receptor HER2. Approved drugs for HER2 positive breast cancer lose their efficacy in many patients eventually as drug resistance develops; the causes are not sufficiently known to develop more effective new medicines. Our goals are to: A) Establish a new analytical process for cancer research and diagnosis, B) gain new insights into drug resistance, C) optimize the drugs personalized to a patient by analyzing biopsy samples to reduce the risk of drug resistance.

Here you can get further information.